Literature DB >> 18500454

Bosentan: a rapidly expanding role in the management of cardio-thoracic diseases.

Shailendra Kapoor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18500454     DOI： 10.1007/s00296-008-0627-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

1.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

2.  Bosentan in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  R Hughes; P George; J Parameshwar; F Cafferty; J Dunning; N W Morrell; J Pepke-Zaba
Journal:  Thorax       Date:  2005-08       Impact factor: 9.139

3.  Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.

Authors:  Nazzareno Galiè; Maurice Beghetti; Michael A Gatzoulis; John Granton; Rolf M F Berger; Andrea Lauer; Eleonora Chiossi; Michael Landzberg
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

4.  A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Authors:  Richard Kefford; Jane McNeil Beith; Guy Arthur Van Hazel; Michael Millward; James Marshall Trotter; David Keith Wyld; Rada Kusic; Revati Shreeniwas; Adele Morganti; Andrea Ballmer; Eleonor Segal; Oliver Nayler; Martine Clozel
Journal:  Invest New Drugs       Date:  2006-10-05       Impact factor: 3.850

5.  The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

Authors:  Sandra Bien; Alexander Riad; Christoph A Ritter; Matthias Gratz; Florian Olshausen; Dirk Westermann; Markus Grube; Thomas Krieg; Sabine Ciecholewski; Stephan B Felix; Alexander Staudt; Heinz-Peter Schultheiss; Ralf Ewert; Uwe Völker; Carsten Tschöpe; Heyo K Kroemer
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

6.  N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH.

Authors:  Sara Simeoni; Giuseppe Lippi; Antonio Puccetti; Martina Montagnana; Elisa Tinazzi; Daniele Prati; Roberto Corrocher; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2007-12-19       Impact factor: 2.631

7.  Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.

Authors:  Michael A Gatzoulis; Maurice Beghetti; Nazzareno Galiè; John Granton; Rolf M F Berger; Andrea Lauer; Eleonora Chiossi; Michael Landzberg
Journal:  Int J Cardiol       Date:  2007-07-20       Impact factor: 4.164

8.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

9.  Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema.

Authors:  Kilkil Gamze; Hamdi Muz Mehmet; Figen Deveci; Teyfik Turgut; Fulya Ilhan; Ibrahim Ozercan
Journal:  Exp Mol Med       Date:  2007-10-31       Impact factor: 8.718

Review 10.  Endothelin receptor antagonists in cancer therapy.

Authors:  Mihailo Lalich; Douglas G McNeel; George Wilding; Glenn Liu
Journal:  Cancer Invest       Date:  2007-12       Impact factor: 2.176
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.